Search results for "Amikacin"

showing 10 items of 18 documents

Which non-carbapenem antibiotics are active against extended-spectrum β-lactamase-producing Enterobacteriaceae?

2018

In this study, the activity of 18 non-carbapenem antibiotics was evaluated against 100 extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (ESBL-Ec) and 50 ESBL-producing Klebsiella pneumoniae (ESBL-Kp) isolated from urinary tract infections and bacteraemia in 2016. Minimum inhibitory concentrations (MICs) were determined using reference methods and the susceptibility profiles were defined according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) 2017 recommendations. All of the ESBL-Ec isolates were susceptible to ceftazidime/avibactam and a great majority of them were susceptible to fosfomycin (98%), piperacillin/tazobactam (97%), amikacin (97%) and nitr…

0301 basic medicineKlebsiella pneumoniaePenicillanic AcidCeftazidimeCeftazidimechemistry.chemical_compoundAntibiotics[ SDV.MP ] Life Sciences [q-bio]/Microbiology and Parasitologypolycyclic compoundsPharmacology (medical)biologyEnterobacteriaceae InfectionsGeneral MedicineAnti-Bacterial Agents3. Good healthDrug CombinationsKlebsiella pneumoniaeInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyAmikacinUrinary Tract InfectionsCeftolozanemedicine.drugMicrobiology (medical)TazobactamAvibactam030106 microbiologyMicrobial Sensitivity TestsTazobactambeta-LactamasesMicrobiology03 medical and health sciencesEnterobacteriaceaemedicineEscherichia coliHumansMecillinambusiness.industrybiochemical phenomena metabolism and nutritionbiology.organism_classificationbacterial infections and mycosesCephalosporinsAlternativesCarbapenemschemistryESBLSusceptibilitybacteriabusinessAzabicyclo CompoundsPiperacillin
researchProduct

Evaluation of a mass spectrometry and Vitek 2 combined protocol for rapid identification and susceptibility testing of Enterobacterales directly from…

2020

Abstract Objective The aim was to evaluate a rapid method which would combine identification and susceptibility testing directly from positive blood cultures for Gram-negative bacilli of the Enterobacterales. Material and methods Gram-negative rods from blood cultures were directly identified by MALDI-TOF. Samples with Enterobacterales were selected for direct antimicrobial susceptibility testing by Vitek 2. The results were compared to those obtained with our laboratory's standard method. Results MALDI-TOF directly from blood cultures identified correctly 83% of the samples. Enterobacterales (n = 68) were identified at gender and species level in 85% of blood cultures with a score >1.7. In…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtySusceptibility testing030106 microbiologyAntimicrobial susceptibilityBacteremiaMicrobial Sensitivity Tests03 medical and health sciences0302 clinical medicineSpecies levelEnterobacteriaceaeInternal medicineEnterobacteralesmedicineHumans030212 general & internal medicineProtocol (science)business.industryAnti-Bacterial AgentsRapid identificationCiprofloxacinAmikacinBlood CultureSpectrometry Mass Matrix-Assisted Laser Desorption-Ionizationbusinessmedicine.drugEnfermedades infecciosas y microbiologia clinica (English ed.)
researchProduct

High susceptibility of MDR and XDR Gram-negative pathogens to biphenyl-diacetylene-based difluoromethyl-allo-threonyl-hydroxamate LpxC inhibitors

2016

International audience; Inhibitors of uridine diphosphate-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC, which catalyses the first, irreversible step in lipid A biosynthesis) are a promising new class of antibiotics against Gram-negative bacteria. The objectives of the present study were to: (i) compare the antibiotic activities of three LpxC inhibitors (LPC-058, LPC-011 and LPC-087) and the reference inhibitor CHIR-090 against Gram-negative bacilli (including MDR and XDR isolates); and (ii) investigate the effect of combining these inhibitors with conventional antibiotics.MethodsMICs were determined for 369 clinical isolates (234 Enterobacteriaceae and 135 non-fermentati…

Acinetobacter baumanniiThreonine0301 basic medicineMicrobiology (medical)Klebsiella pneumoniaemedicine.drug_class030106 microbiologyAntibioticsMicrobial Sensitivity TestsHydroxamic Acidsmedicine.disease_causebeta-LactamasesAmidohydrolasesMicrobiology03 medical and health sciencesBacterial ProteinsEnterobacteriaceae[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyDrug Resistance Multiple BacterialGram-Negative BacteriaEscherichia colipolycyclic compoundsmedicineHumansPharmacology (medical)Enzyme InhibitorsOriginal ResearchPharmacologybiologyPseudomonas aeruginosaEnterobacteriaceae Infectionsbiochemical phenomena metabolism and nutritionbacterial infections and mycosesAntimicrobialbiology.organism_classificationEnterobacteriaceaeAnti-Bacterial Agents3. Good healthAcinetobacter baumanniiCiprofloxacinKlebsiella pneumoniae[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyInfectious DiseasesAmikacinPseudomonas aeruginosalipids (amino acids peptides and proteins)medicine.drugJournal of Antimicrobial Chemotherapy
researchProduct

Re: Antimicrobial Resistance in More Than 100,000 Escherichia coli Isolates According to Culture Site and Patient Age, Gender, and Location

2011

ABSTRACT Escherichia coli and the antimicrobial pressure exerted on this microorganism can be modulated by factors dependent on the host. In this paper, we describe the distribution of antimicrobial resistance to amikacin, tobramycin, ampicillin, amoxicillin clavulanate, cefuroxime, cefoxitin, cefotaxime, imipenem, ciprofloxacin, fosfomycin, nitrofurantoin, and trimetoprim-sulfametoxazole in more than 100,000 E. coli isolates according to culture site and patient age, gender, and location. Bayesian inference was planned in all statistical analysis, and Markov chain Monte Carlo simulation was employed to estimate the model parameters. Our findings show the existence of a marked difference in…

AdultMaleCefotaximeAdolescentmedicine.drug_classUrologyAntibioticsCefotaximeDrug resistanceFosfomycinBiologymedicine.disease_causeEpidemiology and SurveillanceMicrobiologyYoung AdultAntibiotic resistanceFosfomycinCiprofloxacinPatient ageDrug Resistance Multiple BacterialEscherichia coliHumansMedicinePharmacology (medical)ChildAmikacinEscherichia coliEscherichia coli InfectionsAgedRetrospective StudiesAntibacterial agentAged 80 and overPharmacologybusiness.industryInfantMiddle AgedAntimicrobialAnti-Bacterial AgentsImipenemInfectious DiseasesNitrofurantoinAmikacinChild PreschoolTobramycinAmpicillinFemalebusinessmedicine.drugJournal of Urology
researchProduct

Effectiveness and safety of once-daily aminoglycosides: A meta-analysis

1996

The effectiveness and safety of once-daily versus several-times-daily aminoglycosides were studied in a meta-analysis. MEDLINE for 1988 to 1995 was searched, and additional studies were identified from review articles and references in retrieved articles. Studies selected for meta-analysis were randomized controlled clinical trials in nonneutropenic adult patients comparing the clinical effectiveness or nephrotoxicity or ototoxicity of once-daily with several-times-daily aminoglycosides. Differences between groups were expressed as odds ratios. The results were combined by the procedure of Mantel and Haenszel, and 95% confidence intervals and exact confidence intervals were computed. An odd…

Adultmedicine.medical_specialtyMEDLINEInfectionsDrug Administration ScheduleNephrotoxicityOtotoxicityInternal medicinemedicineHumansNetilmicinEar DiseasesAmikacinAgedAntibacterial agentPharmacologybusiness.industryHealth PolicyOdds ratioMiddle Agedmedicine.diseaseConfidence intervalAnti-Bacterial AgentsSurgeryClinical trialMeta-analysisKidney DiseasesControlled Clinical Trials as TopicGentamicinsbusinessAmerican Journal of Health-System Pharmacy
researchProduct

ESBL-producing Klebsiella pneumoniae in a University hospital: Molecular features, diffusion of epidemic clones and evaluation of cross-transmission.

2021

The worldwide spread of Klebsiella pneumoniae producing extended-spectrum β-lactamase (ESBL-Kp) is a significant threat. Specifically, various pandemic clones of ESBL-Kp are involved in hospital outbreaks and caused serious infections. In that context, we assessed the phenotypic and molecular features of a collection of ESBL-Kp isolates in a French university hospital and evaluated the occurrence of potential cross-transmissions. Over a 2-year period (2017–2018), 204 non-duplicate isolates of ESBL-Kp were isolated from clinical (n = 118, 57.8%) or screening (n = 86, 42.2%) sample cultures. These isolates were predominantly resistant to cotrimoxazole (88.8%) and ofloxacin (82.8%) but remaine…

ImipenemNosocomial InfectionsEpidemiologyKlebsiella pneumoniaePathology and Laboratory MedicineKlebsiella PneumoniaeHospitals UniversityMedical ConditionsKlebsiellaDrug Resistance Multiple BacterialPandemicMedicine and Health Sciences0303 health sciencesMultidisciplinarybiologyQRHospitalsBacterial PathogensAnti-Bacterial AgentsBacterial Typing Techniques3. Good healthIntensive Care UnitsInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyMedical MicrobiologyAmikacinGenetic EpidemiologyMedicinePathogensResearch Articlemedicine.drugScienceContext (language use)Research and Analysis MethodsMicrobiologybeta-LactamasesMicrobiology03 medical and health sciencesmedicineHumansGenetic variabilityMolecular Biology TechniquesMolecular BiologyMicrobial PathogensRetrospective Studies030304 developmental biologyBacteria030306 microbiologyOrganismsBiology and Life SciencesOutbreakbiochemical phenomena metabolism and nutritionbiology.organism_classificationbacterial infections and mycosesKlebsiella InfectionsHealth CareHealth Care FacilitiesMultilocus sequence typing[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyCloningPLoS ONE
researchProduct

Clinicopathological profile of gastrointestinal tuberculosis: a multinational ID-IRI study

2020

Data are relatively scarce on gastro-intestinal tuberculosis (GITB). Most studies are old and from single centers, or did not include immunosuppressed patients. Thus, we aimed to determine the clinical, radiological, and laboratory profiles of GITB. We included adults with proven GITB treated between 2000 and 2018. Patients were enrolled from 21 referral centers in 8 countries (Belgium, Egypt, France, Italy, Kazakhstan, Saudi Arabia, UK, and Turkey). One hundred four patients were included. Terminal ileum (n = 46, 44.2%), small intestines except terminal ileum (n = 36, 34.6%), colon (n = 29, 27.8%), stomach (n = 6, 5.7%), and perianal (one patient) were the sites of GITB. One-third of all p…

MaleCirrhosismedicine.medical_treatmentretrospective studylaparoscopyColonoscopymultimodal imagingComorbidityGastroenterologyprotionamide0302 clinical medicineLaparotomyAscitesamikacinMedicinebedaquilinePathologie maladies infectieusesintestine biopsyadultsteroidclinical trialGeneral MedicinerifabutinMicrobiologie et protistologie [entomologiephytoparasitolog.]priority journaldiabetes mellitushistopathologybiological productMicrobiology (medical)Microbiologie et protistologie [parasitologie hum. et anim.]medicine.medical_specialtyTuberculosis030106 microbiologymalignant neoplasmArticle03 medical and health scienceslaparotomyHuman immunodeficiency virus infectionmolecular diagnosisHumansTuberculosisGastro-intestinalhumanRetrospective Studiescolondisease predispositionmicrobiologyTuberculosis; Immune-suppression; Gastro-intestinal; Endoscopy;anusmedicine.diseasemajor clinical studymulticenter studyaminosalicylic acidcyclophosphamide0301 basic medicineBiopsyAntitubercular Agentsethambutolrifampicinterminal ileumcolonoscopyofloxacin030212 general & internal medicineLaparoscopyazathioprinemedicine.diagnostic_testIncidence (epidemiology)gastrointestinal tuberculosisDisease Managementchronic kidney failurecycloserineInfectious DiseasesfemaleTreatment OutcomeMolecular Diagnostic Techniquesdiagnostic testDisease Susceptibilitymedicine.symptommoxifloxacinSymptom AssessmentImmune-suppressionstomachisoniazidpyrazinamidestreptomycinliver cirrhosispatient referrallinezolidInternal medicineBiopsybusiness.industryEndoscopyMycobacterium tuberculosishuman tissueclinical featureTreatmentTuberculosis Gastrointestinaltuberculostatic agentbusinessMicrobiologie et protistologie [bacteriol.virolog.mycolog.]
researchProduct

Extended-spectrum beta-lactamase-producing and carbapenemase-producing Enterobacter cloacae ventriculitis successfully treated with intraventricular …

2014

SummaryWe present a case of post-neurosurgical ventriculitis caused by carbapenemase-producing Enterobacter cloacae successfully treated with intraventricular colistin. Enterobacter spp are intrinsically resistant to aminopenicillins, cefazolin, and cefoxitin due to the production of constitutive chromosomal AmpC beta-lactamases. Moreover, extended-spectrum beta-lactamase-producing Enterobacter spp have been identified in the USA and Europe, and carbapenems are considered the drug of choice in these cases. Our isolate was sensitive only to fosfomycin, tigecycline, and colistin, and 6 days of intravenous colistin had failed to eradicate the infection. This case provides clinical evidence to …

MaleMicrobiology (medical)Intraventricularmedicine.medical_treatmentTigecyclineFosfomycinCeftazidimebeta-LactamasesCerebral VentriculitisMicrobiologyBacterial ProteinsEnterobacteriaceaeDrug Resistance Multiple BacterialEnterobacter cloacaeVentriculitispolycyclic compoundsVentriculitismedicineHumansMeningitisCefoxitinCarbapenemases Colistin Enterobacter cloacaeAmikacinbiologyColistinbusiness.industryEnterobacteriaceae InfectionsGeneral MedicineEnterobacterbiochemical phenomena metabolism and nutritionCarbapenemasesbacterial infections and mycosesmedicine.diseasebiology.organism_classificationAnti-Bacterial AgentsTreatment OutcomeInfectious DiseasesChild PreschoolBeta-lactamaseColistinbacteriaAdministration Intravenouslipids (amino acids peptides and proteins)TeicoplaninbusinessEnterobacter cloacaemedicine.drugInternational Journal of Infectious Diseases
researchProduct

Klebsiella oxitoca folliculitis mimicking tinea barbae in a diabetic man

2005

A 55-year-old male dairy farmer was admitted to our hospital with a skin infection on the neck and face. He was apparently in good general health, and his medical history was unremarkable. He reported that, 50 days before admission, a pruritic red maculopapular rash had developed on the anterior region of his neck. This rash failed to improve after a 10-day course of trimethoprim-sufamethoxazole and fluconazole; rather it progressively worsened. On admission, examination revealed confluent follicular papulae-pustules with purulent-hematic exudation and crusting, on an erythematous-edematous area extending over the anterior region of the neck, chin and mandible (Fig. 1); hairs within the aff…

MalePathologymedicine.medical_specialtyScarsCeftazidimeFolliculitisDermatologyCeftazidimeDiabetes ComplicationsmedicineMaculopapular rashHumansAmikacinTinea barbaeMycosismedicine.diagnostic_testbusiness.industryAmikacin Anti-Bacterial Agents CeftazidimeDiabetes ComplicationsKlebsiella oxytocaMiddle Agedmedicine.diseaseRashDermatologyAnti-Bacterial AgentsKlebsiella InfectionsTreatment OutcomeFaceErythrocyte sedimentation ratemedicine.symptombusinessmedicine.drugInternational Journal of Dermatology
researchProduct

Combination of aztreonam, ceftazidime–avibactam and amikacin in the treatment of VIM-1 Pseudomonas aeruginosa ST235 osteomyelitis

2021

Abstract We describe a challenging case of patient with metallo-beta-lactamase-producing Pseudomonas aeruginosa sternal osteomyelitis following aortic valve replacement with biological prosthesis. The strain exhibited a multidrug-resistance phenotype carrying the blaVIM-1 gene and belonged to the high-risk clone sequence type ST235. The patient was successfully treated with surgical debridement plus antibiotic therapy with ceftazidime/avibactam, aztreonam, and amikacin. Time-kill curves showed that this triple antibiotic combination at 1 × MIC was strongly synergic after 8 h, achieving 99.9% killing and maintaining this until 48 h.

Microbiology (medical)AvibactamDrug ResistanceCeftazidimeInfectious and parasitic diseasesRC109-216Aztreonammedicine.disease_causeST235CeftazidimeMicrobiologyCeftazidime–avibactamchemistry.chemical_compoundAztreonamAortic valve replacementDrug TherapyDrug Resistance Multiple BacterialmedicineHumansPseudomonas InfectionsPseudomonas aeruginosa; ST235; VIM-1; aztreonam; ceftazidime-avibactam; osteomyelitisAmikacinAgedPseudomonas aeruginosabusiness.industryceftazidime-avibactamOsteomyelitisBacterialOsteomyelitisGeneral MedicineCeftazidime/avibactammedicine.diseaseAnti-Bacterial AgentsDrug CombinationsInfectious DiseaseschemistryDebridementAmikacinPseudomonas aeruginosaCombinationVIM-1Drug Therapy CombinationFemalebusinessAzabicyclo CompoundsMultiplemedicine.drug
researchProduct